NCT05642377View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

January 31, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

HGR4113

Once-daily oral administration

DRUG

Placebo

Once-daily oral administration

DRUG

HGR4113

Twice-daily oral administration

DRUG

Placebo

Twice-daily oral administration

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Glaceum
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

lead

Glaceum

INDUSTRY

NCT05642377 - A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects | Biotech Hunter | Biotech Hunter